Beyond Air’s LungFit PH Receives the US FDA’s Approval for the Treatment of Hypoxic Respiratory Failure in Term and Near-Term Neonates

Shots:

The US FDA has approved LungFit PH to treat hypoxic respiratory failure in term and near-term neonates. The device uses the company’s patented Ionizer technology to generate unlimited, on-demand nitric oxide using ambient air. LungFit PH is expected to be available in the H1’23
LungFit PH creates electrical discharge pulses b/w 2 electrodes in a plasma chamber using a compressor to circulate air in the space
It produces nitric oxide with low NO2 as a byproduct by ionising nitrogen and oxygen molecules with the power of a 60W lightbulb. This is the 1st FDA-approved product and eliminates the need for traditional nitric oxide tanks in hospitals setting and the associated burdens to providers

Ref: GlobalNewswire | Image: Beyond Air